Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Biotechnology

Healthcare
$6.77 +1.96%

+$0.19 today

Market cap
$68.98M
Beta
0.11
P/E (TTM)
-14.7
EPS (TTM)
-$0.67
52W Low $3.92High $19.15

Volume 0.02M

Average 1.40M

ATRA Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Atara Biotherapeutics, Inc.NASDAQ: ATRA

Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue falls 95.7% from a year ago

Deferred revenue stood at $684K at the end of Q1 FY2026, down 95.7% from a year earlier and down 4.5% from the prior quarter. Over 3 fiscal years it compounded at -55.3% a year.

Context

  • Deferred revenue amounted to 3.4% of total assets at the end of Q1 FY2026, down 22.3 pp from a year earlier.
  • Deferred revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether deferred revenue keeps falling in the next quarterly balance sheet after a -95.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$684K-4.5% QoQ
Last fiscal yearDec 2025
$716K-99.2% YoY
Year agoMar 2025
$15.98M-95.7% since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-95.7%——
1 year-99.2%——
3-year CAGR-55.3%——
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
716K USD
Year-over-year change
-99.2%
4-year CAGR
-63.6%

Deferred Revenue vs competitors

How ATRA compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -95.7% is the lowest of 6, against a peer median of -8.5%.
  • Deferred revenue amounts to 3.4% of total assets for ATRA, versus a peer median of 0.8%.
ATRA Competitors
Deferred Revenue for ATRA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MGNXMacroGenics, Inc.Mar 2026$67.99M USD+335.3%+3.0%31.2%
CSBRChampions Oncology, Inc.Jan 2026$10M USD-8.5%+11.7%35.1%
STROSutro Biopharma, Inc.Mar 2026$9.4M USD-86.4%-14.3%3.9%
ORMPOramed Pharmaceuticals Inc.Mar 2026$1.47M USD—+0.3%0.5%
COYACoya Therapeutics, Inc.Mar 2026$1.24M USD+47.7%—2.3%
ATRAAtara Biotherapeutics, Inc.Mar 2026$684K USD-95.7%-55.3%3.4%
CLNNClene Inc.Mar 2026$219K USD-51.9%+42.6%1.0%
OVIDOvid Therapeutics Inc.Mar 2026$0 USD——0.0%
STTKShattuck Labs, Inc.Mar 2026$0 USD——0.0%
IFRXInflaRx N.V.Mar 2026€0 EUR——0.0%
CNTXContext Therapeutics Inc.Mar 2026$0 USD——0.0%
Peer median (excluding ATRA) —-8.5%+3.0%0.8%

Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents106.08M92.94M25.84M25.03M8.48M
Short-term Investments264.98M149.88M25.88M17.47M0
Net Receivables986K40.22M34.11M1.48M1.25M
Inventory01.59M9.71M10.66M0
Other Current Assets194K10.45M6.33M10.26M2.48M
Total Current Assets384.62M295.08M101.87M64.89M12.21M
Property, Plant & Equipment (Net)79.94M74.32M58.79M41.1M7.14M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets3.57M7.02M4.84M3.1M886K
Total Non-current Assets83.51M81.34M63.64M44.2M8.02M
Total Assets468.13M376.42M165.5M109.1M20.24M
Account Payables17.37M6.87M3.68M4.37M127K
Short-term Debt000010.78M
Tax Payables00000
Deferred Revenue40.76M8M77.83M95.09M716K
Other Current Liabilities25.15M32.75M37.01M6.59M2.03M
Total Current Liabilities105.79M78.92M142.23M134.57M14.92M
Long-term Debt000032.67M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)55.71M77M37.56M00
Other Non-current Liabilities1.5M35.8M39.25M41.89M1.8M
Total Non-current Liabilities82.73M170.86M122.51M71.81M43.82M
Total Liabilities188.51M249.78M264.74M206.38M58.74M
Common Stock9K10K11K1K1K
Retained Earnings(1.46B)(1.69B)(1.97B)(2.05B)(2.02B)
Accumulated OCI(368K)(2.07M)(204K)8K1K
Other Stockholders Equity00000
Minority Interest00000
Total Equity279.61M126.64M(99.23M)(97.28M)(38.5M)
Total Debt28.27M71.7M57.87M43.83M52.8M
Net Debt(77.81M)(21.24M)32.03M18.8M44.32M

Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.